These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16540934)

  • 1. Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy.
    Giancola ML; Lorenzini P; Balestra P; Larussa D; Baldini F; Corpolongo A; Narciso P; Bellagamba R; Tozzi V; Antinori A
    J Acquir Immune Defic Syndr; 2006 Mar; 41(3):332-7. PubMed ID: 16540934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.
    Tozzi V; Balestra P; Bellagamba R; Corpolongo A; Salvatori MF; Visco-Comandini U; Vlassi C; Giulianelli M; Galgani S; Antinori A; Narciso P
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):174-82. PubMed ID: 17356465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.
    Tozzi V; Balestra P; Salvatori MF; Vlassi C; Liuzzi G; Giancola ML; Giulianelli M; Narciso P; Antinori A
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):56-63. PubMed ID: 19731418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients.
    Cysique LA; Maruff P; Brew BJ
    Neurology; 2006 May; 66(9):1447-50. PubMed ID: 16682686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.
    Eggers C; Hertogs K; Stürenburg HJ; van Lunzen J; Stellbrink HJ
    AIDS; 2003 Sep; 17(13):1897-906. PubMed ID: 12960822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.
    Marra CM; Zhao Y; Clifford DB; Letendre S; Evans S; Henry K; Ellis RJ; Rodriguez B; Coombs RW; Schifitto G; McArthur JC; Robertson K;
    AIDS; 2009 Jul; 23(11):1359-66. PubMed ID: 19424052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia.
    Sevigny JJ; Albert SM; McDermott MP; McArthur JC; Sacktor N; Conant K; Schifitto G; Selnes OA; Stern Y; McClernon DR; Palumbo D; Kieburtz K; Riggs G; Cohen B; Epstein LG; Marder K
    Neurology; 2004 Dec; 63(11):2084-90. PubMed ID: 15596754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
    Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E
    Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility.
    Fabbiani M; Grima P; Milanini B; Mondi A; Baldonero E; Ciccarelli N; Cauda R; Silveri MC; De Luca A; Di Giambenedetto S
    Antivir Ther; 2015; 20(4):441-7. PubMed ID: 25516553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women.
    Cohen RA; Boland R; Paul R; Tashima KT; Schoenbaum EE; Celentano DD; Schuman P; Smith DK; Carpenter CC
    AIDS; 2001 Feb; 15(3):341-5. PubMed ID: 11273214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study.
    Lawler K; Mosepele M; Ratcliffe S; Seloilwe E; Steele K; Nthobatsang R; Steenhoff A
    J Int AIDS Soc; 2010 Apr; 13():15. PubMed ID: 20406460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurocognitive impairment in HIV-infected naïve patients with advanced disease: the role of virus and intrathecal immune activation.
    Airoldi M; Bandera A; Trabattoni D; Tagliabue B; Arosio B; Soria A; Rainone V; Lapadula G; Annoni G; Clerici M; Gori A
    Clin Dev Immunol; 2012; 2012():467154. PubMed ID: 22489249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort.
    Smurzynski M; Wu K; Letendre S; Robertson K; Bosch RJ; Clifford DB; Evans S; Collier AC; Taylor M; Ellis R
    AIDS; 2011 Jan; 25(3):357-65. PubMed ID: 21124201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control.
    Calcagno A; Simiele M; Alberione MC; Bracchi M; Marinaro L; Ecclesia S; Di Perri G; D'Avolio A; Bonora S
    Clin Infect Dis; 2015 Jan; 60(2):311-7. PubMed ID: 25281609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
    Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
    HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurocognitive Impairment in the Combined Antiretroviral Therapy Era in a Romanian Cohort of Young Adults with Chronic HIV Infection.
    Temereanca A; Ene L; Rosca A; Diaconu CC; Luca A; Burlacu R; Radoi R; Bulacu-Talnariu A; Marcotte TD; Achim CL; Ruta S
    AIDS Res Hum Retroviruses; 2020 May; 36(5):367-372. PubMed ID: 31476875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF penetration by antiretroviral drugs.
    Eisfeld C; Reichelt D; Evers S; Husstedt I
    CNS Drugs; 2013 Jan; 27(1):31-55. PubMed ID: 23160938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infection.
    Childers ME; Woods SP; Letendre S; McCutchan JA; Rosario D; Grant I; Mindt MR; Ellis RJ;
    J Neurovirol; 2008 Nov; 14(6):550-7. PubMed ID: 19016380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function.
    Ferrando S; van Gorp W; McElhiney M; Goggin K; Sewell M; Rabkin J
    AIDS; 1998 May; 12(8):F65-70. PubMed ID: 9631133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.